What is the expected growth forecast for the CKD-MBD market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing prevalence.

What are the key drivers of the CKD-MBD market?

Key drivers include rising cases of chronic kidney disease and growing demand for dialysis services.

What are the major challenges facing the CKD-MBD market?

Challenges include high treatment costs and limited access to healthcare services in developing regions.

Which regions are leading the CKD-MBD market?

North America and Europe are leading the market due to high healthcare expenditure and awareness.

Who are the top companies in the CKD-MBD market?

Top companies include Amgen, Sanofi, and Pfizer, which offer a range of treatments and therapies.

What future opportunities exist in the CKD-MBD market?

Opportunities include development of new therapies and expansion into emerging markets with growing demand.

How is technology impacting the CKD-MBD market?

Technology is improving diagnosis and treatment options, with advances in dialysis and digital health platforms.

What is the current regulatory landscape for the CKD-MBD market?

The regulatory landscape is evolving, with a focus on patient safety and efficacy of new treatments and therapies.

What is the future outlook for the CKD-MBD market?

The future outlook is positive, with growing demand and increasing investment in research and development.

Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) by Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores, Others), by Types (Control Hyperphosphatemia, Maintain Blood Calcium Levels, Control PTH Level, Correct Acidosis, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Size | CAGR 10.2 Forecast 2033

Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Overview

The Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market refers to the industry focused on managing and treating mineral and bone disorders associated with chronic kidney disease. As a significant aspect of the healthcare sector, the Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market size is anticipated to experience substantial growth, driven by an increasing prevalence of chronic kidney disease and a growing awareness of the importance of early diagnosis and treatment. The growth outlook for the CKD-MBD market is positive, with a market forecast indicating a compound annual growth rate (CAGR) of around 7.8% from 2026 to 2033, reaching approximately $14.5 billion by 2033. This industry expansion is attributed to advancements in treatment options, improvements in healthcare infrastructure, and increased investments in research and development.

Loading chart…

Key forces shaping the CKD-MBD industry include technology shifts towards more personalized and targeted therapies, regulations aimed at improving patient safety and treatment efficacy, and changes in consumer behavior with a greater emphasis on preventive care. The largest region in the CKD-MBD market is currently North America, while the fastest-growing region is expected to be the Asia-Pacific, driven by increasing healthcare expenditures and a growing awareness of CKD-MBD. As the CKD-MBD market continues to evolve, it is essential for industry stakeholders to stay informed about the latest trends, challenges, and opportunities to ensure competitive intensity and supply-chain dynamics support the growth of this critical sector.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Akebia; Astellas; Takeda; Vifor; Abbvie; Fresenius; Abbott; Novadiol; Japan Tobacco Company; Daiichi-Sankyo; Shield; Spectrum; OPKO; Ardelyx; Sanofi Genzyme; Amgen
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market is experiencing significant growth, driven by various factors. The Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market size is expected to increase substantially over the forecast period, with a promising growth forecast.

Growth Drivers2 items

Increasing prevalence of chronic kidney disease and related mineral and bone disorders, driving demand for effective treatments and therapies

Advances in medical technology and research, leading to the development of innovative diagnostic and therapeutic solutions for CKD-MBD

Restraints2 items

High costs associated with CKD-MBD treatments and therapies, limiting accessibility for patients in developing regions

Stringent regulatory frameworks and reimbursement policies, hindering the adoption of new CKD-MBD treatments and therapies

Opportunities2 items

Growing awareness about CKD-MBD and its management, creating opportunities for market players to develop and market educational programs and awareness campaigns

Increasing focus on personalized medicine and targeted therapies, enabling companies to develop tailored solutions for CKD-MBD patients

Challenges2 items

Managing the complexity of CKD-MBD, which requires a comprehensive approach to diagnosis, treatment, and management

Addressing the economic burden of CKD-MBD, which is a significant concern for patients, healthcare systems, and market players

Market Segmentation

Loading chart…

The Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market can be segmented based on Application, which includes diagnosis, treatment, and prevention of CKD-MBD. This segmentation contributes to the overall market size by providing insights into the various uses of CKD-MBD products and services. Understanding the application segment is crucial for stakeholders to identify opportunities and challenges in the market. The Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) segmentation by application helps in market taxonomy and analysis.

The Types segment of the CKD-MBD market includes subtypes such as [object Object],[object Object]. This segmentation is essential to understand the different types of CKD-MBD products and services available in the market. Each subtype has its own unique characteristics, advantages, and disadvantages, which affect the overall market size. Analyzing the types segment helps stakeholders to identify the most promising areas of growth and investment in the CKD-MBD market. The types segment is a critical component of the Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market taxonomy.

Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Segmentation Breakdown12 items

Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Drug Stores

Others

Types

Control Hyperphosphatemia

Maintain Blood Calcium Levels

Control PTH Level

Correct Acidosis

Others

Regional Insights

Loading chart…

The Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market growth is expected to vary across regions, with the largest share held by North America, accounting for approximately 35% of the global market. The Asia Pacific region is anticipated to be the fastest-growing, driven by increasing adoption of CKD-MBD treatments, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and established infrastructure. In Europe, drivers include a strong regulatory framework, increasing adoption of CKD-MBD therapies, and a large patient population. The Asia Pacific region is driven by rapid urbanization, growing healthcare expenditure, and increasing awareness of CKD-MBD. Latin America and Middle East & Africa are expected to experience growth due to improving infrastructure, rising healthcare spending, and a growing patient population.

Competitive Landscape

The Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) competitive landscape is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The market is driven by both global players, who leverage their extensive resources and distribution networks, and local companies, which often focus on regional expertise and tailored product offerings. Key competitive levers include pricing strategies, partnerships, and product innovation, as companies strive to differentiate themselves in a crowded market.

Companies in the CKD-MBD market employ various strategies to differentiate themselves and maintain competitiveness. Common strategies include mergers and acquisitions, partnerships, product launches, expansion into new regions, research and development, and localization of products. However, companies face challenges such as margin pressure, compliance costs, and commoditization, which can erode their competitive advantages. To overcome these challenges, companies focus on technology, service models, channel strength, customization, and cost advantages to differentiate themselves. The following companies illustrate this trend:

Akebia: regional expansion

Astellas: innovation pipeline

Takeda: vertical integration

Vifor: premium pricing

Abbvie: OEM tie-ups

Fresenius: local manufacturing

Key Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Companies16 items

Akebia

Astellas

Takeda

Vifor

Abbvie

Fresenius

Abbott

Novadiol

Japan Tobacco Company

Daiichi-Sankyo

Shield

Spectrum

OPKO

Ardelyx

Sanofi Genzyme

Amgen

Market Ecosystem

The Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) ecosystem spans upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value is created and captured through the development, manufacturing, and distribution of treatments and technologies that address CKD-MBD. The ecosystem's boundaries are defined by the interactions between these segments, with technology providers and suppliers at the upstream end, and end users, such as healthcare providers and patients, at the downstream end.

Raw material suppliers — providing Active Pharmaceutical Ingredients

OEMs / manufacturers — producing CKD-MBD treatments

Technology providers — developing diagnostic and therapeutic technologies

System integrators / EPCs — integrating CKD-MBD solutions

Distributors / channel partners — delivering CKD-MBD products to healthcare providers

Regulators/standards bodies — establishing guidelines and approvals for CKD-MBD treatments

Service providers / after-sales — offering support and maintenance for CKD-MBD technologies

In the CKD-MBD ecosystem, control points are held by regulators, who influence the adoption of new treatments and technologies through approvals and guidelines. Dependency risks arise from input constraints, such as the availability of raw materials, and standards, which can impact the development and manufacturing of CKD-MBD treatments. Switching costs and partnerships between technology providers and integrators can also affect the ecosystem, as well as interoperability requirements between different technologies and systems. Furthermore, the ecosystem may differ by region due to varying regulatory frameworks and healthcare systems, highlighting the need for a thorough value chain analysis to understand the complex interactions within the CKD-MBD ecosystem.

Recent Industry Insights

The Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships have been formed, such as the collaboration between pharmaceutical companies to develop novel therapeutics for CKD-MBD. Additionally, there have been key mergers and acquisitions, including the acquisition of a biotech firm specializing in CKD-MBD treatments. Recent product launches have also been observed, with a focus on innovative diagnostic tools and personalized treatment options.

Furthermore, regulatory changes have been implemented to enhance the safety and efficacy of CKD-MBD treatments. A shift in consumer trends has also been observed, with an increasing emphasis on preventive care and patient-centric approaches. The industry has also seen significant funding rounds and expansions, with investments in research and development aimed at addressing the growing burden of CKD-MBD. These developments are expected to shape the future of the CKD-MBD industry, driving growth and innovation in the years to come.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market outlook. The market attractiveness is moderate, driven by the increasing prevalence of chronic kidney disease and the need for effective treatments. The competitive intensity is high, with several key players vying for market share. Looking ahead, the long-term outlook is promising, with opportunities for innovation in CKD-MBD therapies. The innovation landscape is evolving, with a focus on personalized medicine and novel therapeutics. However, the demand–supply balance is a concern, with a potential shortage of certain treatments. Key risk factors include regulatory changes and pricing pressures, which may impact market growth.

11 items

1. Executive Summary

2. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital Pharmacies

6.1.2. Retail Pharmacies

6.1.3. Online Pharmacies

6.1.4. Drug Stores

6.1.5. Others

6.2. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Control Hyperphosphatemia

6.2.2. Maintain Blood Calcium Levels

6.2.3. Control PTH Level

6.2.4. Correct Acidosis

6.2.5. Others

6.3. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Competition by Key Manufacturers

8.1. Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Akebia

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Astellas

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Takeda

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Vifor

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Abbvie

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Fresenius

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Abbott

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Novadiol

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Japan Tobacco Company

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Daiichi-Sankyo

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Shield

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Spectrum

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. OPKO

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Ardelyx

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Sanofi Genzyme

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Amgen

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market

Figure 4: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market: Drivers

Figure 5: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market: Challenges

Figure 6: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market: Trends

Figure 7: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market: Opportunity

Figure 8: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market: Restraint

Figure 9: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Value (USD Million) By Region

Figure 15: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Value (USD Million) By Region

Figure 23: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Value (USD Million) By Region

Table 10: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Akebia Basic Information And Sales Area

Table 31: Akebia. Products Portfolio

Table 32: Astellas Basic Information And Sales Area

Table 33: Astellas. Products Portfolio

Table 34: Takeda Basic Information And Sales Area

Table 35: Takeda. Products Portfolio

Table 36: Vifor Basic Information And Sales Area

Table 37: Vifor. Products Portfolio

Table 38: Abbvie Basic Information And Sales Area

Table 39: Abbvie. Products Portfolio

Table 40: Fresenius Basic Information And Sales Area

Table 41: Fresenius. Products Portfolio

Table 42: Abbott Basic Information And Sales Area

Table 43: Abbott. Products Portfolio

Table 44: Novadiol Basic Information And Sales Area

Table 45: Novadiol. Products Portfolio

Table 46: Japan Tobacco Company Basic Information And Sales Area

Table 47: Japan Tobacco Company. Products Portfolio

Table 48: Daiichi-Sankyo Basic Information And Sales Area

Table 49: Daiichi-Sankyo. Products Portfolio

Table 50: Shield Basic Information And Sales Area

Table 51: Shield. Products Portfolio

Table 52: Spectrum Basic Information And Sales Area

Table 53: Spectrum. Products Portfolio

Table 54: OPKO Basic Information And Sales Area

Table 55: OPKO. Products Portfolio

Table 56: Ardelyx Basic Information And Sales Area

Table 57: Ardelyx. Products Portfolio

Table 58: Sanofi Genzyme Basic Information And Sales Area

Table 59: Sanofi Genzyme. Products Portfolio

Table 60: Amgen Basic Information And Sales Area

Table 61: Amgen. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Value (USD Million) By Region

Table 67: Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Akebia; Astellas; Takeda; Vifor; Abbvie; Fresenius; Abbott; Novadiol; Japan Tobacco Company; Daiichi-Sankyo; Shield; Spectrum; OPKO; Ardelyx; Sanofi Genzyme; Amgen
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options